StockNews.com Initiates Coverage on Lipocine (NASDAQ:LPCN)

Stock analysts at StockNews.com initiated coverage on shares of Lipocine (NASDAQ:LPCN) in a report released on Friday. The firm set a “hold” rating on the specialty pharmaceutical company’s stock.

Lipocine Stock Performance

NASDAQ LPCN opened at $3.30 on Friday. Lipocine has a twelve month low of $2.91 and a twelve month high of $11.79. The stock has a market capitalization of $17.65 million, a PE ratio of -4.34 and a beta of 1.42. The stock has a 50-day simple moving average of $3.98 and a 200 day simple moving average of $4.53.

Hedge Funds Weigh In On Lipocine

A hedge fund recently raised its stake in Lipocine stock. Geode Capital Management LLC increased its holdings in shares of Lipocine Inc. (NASDAQ:LPCN) by 6.0% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 57,464 shares of the specialty pharmaceutical company’s stock after purchasing an additional 3,248 shares during the period. Geode Capital Management LLC owned approximately 1.07% of Lipocine worth $280,000 at the end of the most recent reporting period. Hedge funds and other institutional investors own 9.11% of the company’s stock.

About Lipocine

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.